Is a
Clinical Study attributes
NCT Number
Trial Recruitment Size
730
Trial Sponsor
Clinical Trial Start Date
2015
0Primary Completion Date
2017
0Study Completion Date
2017
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Basic Science0
Intervention Type
Drug0
Biological0
Intervention Name
Placebo0
Hepatitis A vaccine0
MGD0100
Interventional Trial Phase
Phase 10
Official Name
A Phase 1, First-in-Human, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of MGD010, a CD32B x CD79B Dual Affinity Re-Targeting (DART®) Bi-specific Antibody-Based Molecule, in Healthy Subjects0
Last Updated
February 8, 2022
0Allocation Type
Randomized0
Intervention Model
Parallel Assignment0
Masking Type
Quadruple0
Masked Party
Participant0
Outcomes Assessor0
Investigator0
Care Provider0
Study summary
The primary goal of this Phase 1 study is to assess the safety and tolerability of one MGD010 intravenous (IV) infusion in healthy adult volunteers.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
